What is Pramlintide?
Pramlintide is an adjunctive diabetes medicine used with mealtime insulin in selected patients. It does not replace insulin.
Biological role or research focus
Adjunctive diabetes treatment with mealtime insulin.
The source emphasizes severe hypoglycemia risk. Its role differs from an ordinary supplement.
Role reference: MedlinePlus · Pramlintide ↗
Names you may encounter
Symlin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Amylin analogue
- Main research area
- Post-meal glucose management
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Pramlintide ↗
Quick answers
- Is Pramlintide FDA approved?
- It was approved but is no longer marketed. Symlin (NDA 021332, approved 2005) as a mealtime add-on to insulin in type 1 and type 2 diabetes; Drugs@FDA now lists it as discontinued. Source ↗
- Is Pramlintide safe?
- Pramlintide (Symlin), an amylin analog once used with mealtime insulin, is discontinued in the US; its label's boxed warning was severe low blood sugar, especially in type 1 diabetes. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Pramlintide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Adjunct-to-insulin trial (2006) | Human randomized trial | 296 people with type 1 diabetes. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2006
Adjunct-to-insulin trial
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
- Population / model
- 296 people with type 1 diabetes.
- Study design
- Twenty-nine weeks; pramlintide or placebo with actively adjusted insulin therapy.
- Main finding
- HbA1c declined by 0.5 percentage points in both groups. Weight changed by −1.3 kg with pramlintide versus +1.2 kg with placebo. Post-meal glucose excursions improved more with pramlintide. Nausea occurred in 63% versus 36%; severe hypoglycemia event rates were 0.57 versus 0.30 per patient-year.
- How to read it
- A severe-hypoglycemia event rate counts events over time and is not the percentage of participants affected. Improvements in post-meal glucose and weight did not translate into superior HbA1c reduction in this trial.
- Limits & context
- The glucose-management protocol included clinician-directed insulin adjustment. A favorable meal-glucose finding should not be described as superior HbA1c reduction or used as a self-treatment protocol.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
61 registered studies name Pramlintide as an intervention; 2 are recruiting or under way, 2 have not started recruiting yet, 43 completed and 14 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Outpatient Pramlintide Study NCT07914621 · Oregon Health and Science University | Not yet recruiting | Not applicable | 2026-11-02 | 26 |
| Postprandial Regulation of Bone Perfusion in Healthy Individuals NCT07679516 · University of Copenhagen | Not yet recruiting | Not applicable | 2026-07-19 | 15 |
| Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide NCT06422325 · Oregon Health and Science University | Completed | Not applicable | 2024-07-12 | 33 |
| Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease NCT03560960 · Boston University | Active, not recruiting | Early phase 1 | 2020-02-04 | 57 |
| Tailoring Obesity Treatment Trial NCT06619015 · Esbjerg Hospital - University Hospital of Southern Denmark | Withdrawn | Phase 2 / Phase 3 | 2025-04-01 | 0 |
| Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans NCT07506369 · University Hospital, Gentofte, Copenhagen | Recruiting | Not applicable | 2026-04 | 18 |
| A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes NCT06046417 · McGill University Health Centre/Research Institute of the McGill University Health Centre | Status unknown | Phase 2 / Phase 3 | 2023-11-30 | 30 |
| Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D NCT04074317 · Xeris Pharmaceuticals | Completed | Phase 2 | 2019-08-22 | 18 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 61 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Amylin: Pharmacology, Physiology, and Clinical Potential. ↗
Pharmacological reviews · 2015 Jul · Journal Article, Research Support, Non-U.S. Gov't, Review
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance. ↗
Endocrine reviews · 2025 May 9 · Journal Article, Review
Read available full text ↗
Development of Cagrilintide, a Long-Acting Amylin Analogue. ↗
Journal of medicinal chemistry · 2021 Aug 12 · Journal Article, Research Support, Non-U.S. Gov't
The story of amylin: from physiology to therapy. ↗
Nature metabolism · 2026 Feb · Journal Article, Review
Risks & interactions
Pramlintide (Symlin), an amylin analog once used with mealtime insulin, is discontinued in the US; its label's boxed warning was severe low blood sugar, especially in type 1 diabetes.
Use with insulin raises the risk of severe low blood sugar, especially in type 1 diabetes. Serious injuries can happen if it occurs while driving, operating heavy machinery or doing other risky activities.
An FDA label exists (DailyMed version dated 2019), and Drugs@FDA lists all Symlin products as discontinued. In one 29-week trial in type 1 diabetes, nausea and severe low blood sugar were more common than with placebo.
Take extra care with: Diabetes or blood-sugar medicines
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Serious allergy to pramlintide or any ingredient
- Hypoglycemia unawareness (not sensing low blood sugar)
- Confirmed gastroparesis (slow stomach emptying)
- Children: excluded by the label's patient-selection criteria
Interactions
- Insulin: higher risk of severe low blood sugar
- Oral medicines such as pain relievers, antibiotics and birth control pills: absorption may be delayed
- Drugs that slow the gut, such as atropine-like anticholinergics, or slow nutrient absorption, such as alpha-glucosidase inhibitors: not studied and not advised
Serious risks
- Severe low blood sugar when used with insulin
- Injuries from low blood sugar while driving or operating machinery
- Delayed absorption of oral medicines from slowed stomach emptying
Common side effects
- nausea
- vomiting
- loss of appetite
- headache
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: SymlinPen (pramlintide) prescribing information ↗ · Drugs@FDA: Symlin, NDA 021332 (discontinued) ↗ · Edelman et al., Diabetes Care 2006: pramlintide with intensive insulin therapy in type 1 diabetes ↗
Key precautions
Severe hypoglycemia is a major concern when combined with insulin. Nausea and delayed absorption of oral medicines also matter; changes in insulin treatment require clinical supervision.
Source: MedlinePlus · Pramlintide ↗
Benefit and harm in the insulin-adjunct trial
Even with proactive clinician-directed insulin adjustment, severe hypoglycemia events were more frequent with pramlintide. Nausea was also more common. The trial protocol is part of the intervention and is not a self-directed insulin-adjustment guide.
Regulatory status
- U.S. FDA approval
- Approved, now discontinued
Symlin (NDA 021332, approved 2005) as a mealtime add-on to insulin in type 1 and type 2 diabetes; Drugs@FDA now lists it as discontinued. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The medication reference describes selected patients whose glucose remains inadequately controlled with existing insulin-based therapy. The cited trial examined active insulin adjustment alongside the added medicine.
Source: MedlinePlus · Pramlintide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Mechanism & research rationale
It slows movement of food through the stomach and moderates post-meal glucose excursions. Appetite and weight may also change.
Source: MedlinePlus · Pramlintide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- The source emphasizes severe hypoglycemia risk. Its role differs from an ordinary supplement.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did pramlintide lower HbA1c more than placebo in this trial?
No. Both groups had similar HbA1c reductions, though post-meal glucose and weight differed.
Source: MedlinePlus · Pramlintide ↗
Can the trial be read as permission to replace insulin?
No. Pramlintide was studied as an adjunct to insulin, not as a replacement.
Why can meal glucose improve without a greater HbA1c reduction?
They measure different aspects of glucose control. In this trial both groups received active insulin optimization; the measured HbA1c reduction was similar despite differences in post-meal excursions.
Does an event rate of 0.57 mean 57% of people had severe hypoglycemia?
No. It is a rate per patient-year and can include repeated events in one person. The abstract does not supply a corresponding participant percentage.
Can these findings establish pramlintide alone for obesity?
No. The study enrolled people with type 1 diabetes and tested pramlintide as an adjunct to actively adjusted insulin. That is a different question from stand-alone obesity treatment.
How complete is this evidence review?
This profile summarizes selected NLM abstracts and linked medicine information. It is not a systematic review. Full-text verification and a comprehensive search have not been done, and this summary has not been reviewed by a medical professional.
References & editorial record
- MedlinePlus · Pramlintide ↗
- A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
